4//SEC Filing
Jenkins John Kenneth 4
Accession 0000950170-25-080311
CIK 0001595097other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 4:30 PM ET
Size
9.4 KB
Accession
0000950170-25-080311
Insider Transaction Report
Form 4
Jenkins John Kenneth
Director
Transactions
- Sale
Common Stock, par value $0.0001 per share
2025-05-30$7.35/sh−2,783$20,465→ 33 total - Award
Common Stock, par value $0.0001 per share
2025-05-30+4,800→ 4,833 total - Award
Stock options (right to buy)
2025-05-30+16,000→ 16,000 totalExercise: $7.42Exp: 2035-05-30→ Common Stock (16,000 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2024.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.21 to $7.53. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
- [F4]This amount includes 4,800 unvested RSUs that were granted on May 30, 2025.
- [F5]The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
Documents
Issuer
Corbus Pharmaceuticals Holdings, Inc.
CIK 0001595097
Entity typeother
Related Parties
1- filerCIK 0001742557
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 4:30 PM ET
- Size
- 9.4 KB